2 results
Approved WMORecruiting
PRIMARY: Dose finding part (Phase 1):To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the recommended Phase 2 doses (RP2Ds) of each…
Approved WMOCompleted
The purpose of this study is to determine whether LCQ908 is effective and safe in lowering triglycerides in subjects with FCS (HLP type I).